Protocol for a Randomised Controlled Trial: Efficacy of Donepezil Against Psychosis in Parkinson's Disease (EDAP)

Overview

Journal BMJ Open

Specialty General Medicine

Date 2013 Sep 28

PMID 24071461

Citations 5

Authors

Hideyuki Sawada

Tomoko Oeda

Affiliations

Soon will be listed here.

Abstract

Introduction: Psychosis, including hallucinations and delusions, is one of the important non-motor problems in patients with Parkinson's disease (PD) and is possibly associated with cholinergic neuronal degeneration. The EDAP (Efficacy of Donepezil against Psychosis in PD) study will evaluate the efficacy of donepezil, a brain acetylcholine esterase inhibitor, for prevention of psychosis in PD.

Methods And Analysis: Psychosis is assessed every 4 weeks using the Parkinson Psychosis Questionnaire (PPQ) and patients with PD whose PPQ-B score (hallucinations) and PPQ-C score (delusions) have been zero for 8 weeks before enrolment are randomised to two arms: patients receiving donepezil hydrochloride or patients receiving placebo. The patients are then followed for 96 weeks. The primary outcome measure is the time to the event, defined as getting 2 points or more on the PPQ-B score or PPQ-C score, which is assessed using a survival time analysis. The hypothesis being tested is that donepezil prevents psychosis in patients with PD. Efficacy will be tested statistically using the intention-to-treat analysis including a log-rank test or Cox proportional hazard models. Secondary outcomes, such as changes of PPQ scores and Unified Parkinson's Disease Rating Scale scores from baseline will be assessed.

Ethics And Dissemination: Ethics approval was received from the Central Review Board of the National Hospital Organization, Tokyo, Japan. The trial was declared and registered to the Pharmaceuticals and Medical Devices Agency(PMDA), Japan (No. 22-4018). All participants will receive a written informed consent that was approved by the Central Review. A completed written informed consent is required to enrol in the study. Severe adverse events will be monitored by investigators and in cases where a severe adverse event was previously unreported, it will be reported to the PMDA.

Clinical Trial Registration Number: UMIN000005403.

Citing Articles

Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years.

Sawada H, Oeda T, Kohsaka M, Umemura A, Tomita S, Park K J Neurol Neurosurg Psychiatry. 2018; 89(12):1332-1340.

PMID: 30076270 PMC: 6288700. DOI: 10.1136/jnnp-2018-318107.

Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.

Taddei R, Cankaya S, Dhaliwal S, Chaudhuri K Parkinsons Dis. 2017; 2017:3256542.

PMID: 29104810 PMC: 5613459. DOI: 10.1155/2017/3256542.

Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.

Samudra N, Patel N, Womack K, Khemani P, Chitnis S Drugs Aging. 2016; 33(12):855-863.

PMID: 27830568 PMC: 6760850. DOI: 10.1007/s40266-016-0416-8.

Psychosis in Parkinson's disease: identification, prevention and treatment.

Levin J, Hasan A, Hoglinger G J Neural Transm (Vienna). 2015; 123(1):45-50.

PMID: 25894288 DOI: 10.1007/s00702-015-1400-x.

Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.

Sawada H, Oeda T, Umemura A, Tomita S, Hayashi R, Kohsaka M PLoS One. 2014; 9(1):e85886.

PMID: 24497930 PMC: 3908859. DOI: 10.1371/journal.pone.0085886.

References

Daniel S, Lees A . Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl. 1993; 39:165-72. View

Ondo W, Tintner R, Voung K, Lai D, Ringholz G . Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005; 20(8):958-63. DOI: 10.1002/mds.20474. View

Manganelli F, Vitale C, Santangelo G, Pisciotta C, Iodice R, Cozzolino A . Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain. 2009; 132(Pt 9):2350-5. PMC: 2800383. DOI: 10.1093/brain/awp166. View

. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340(10):757-63. DOI: 10.1056/NEJM199903113401003. View

Williams D, Lees A . Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 2005; 4(10):605-10. DOI: 10.1016/S1474-4422(05)70146-0. View

Jellinger K . Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol. 1991; 14(3):153-97. DOI: 10.1007/BF03159935. View

Kosasa T, Kuriya Y, Yamanishi Y . Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Jpn J Pharmacol. 1999; 81(2):216-22. DOI: 10.1254/jjp.81.216. View

Adler C . Nonmotor complications in Parkinson's disease. Mov Disord. 2005; 20 Suppl 11:S23-9. DOI: 10.1002/mds.20460. View

Merims D, Shabtai H, Korczyn A, Peretz C, Weizman N, Giladi N . Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm (Vienna). 2004; 111(10-11):1447-53. DOI: 10.1007/s00702-004-0209-9. View

10.

Goetz C, Leurgans S, Pappert E, Raman R, Stemer A . Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001; 57(11):2078-82. DOI: 10.1212/wnl.57.11.2078. View

11.

Rabey J, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C . Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. 2006; 22(3):313-8. DOI: 10.1002/mds.21116. View

12.

Kosasa T, Kuriya Y, Matsui K, Yamanishi Y . Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol. 1999; 380(2-3):101-7. DOI: 10.1016/s0014-2999(99)00545-2. View

13.

Brandstaedter D, Spieker S, Ulm G, Siebert U, Eichhorn T, Krieg J . Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. J Neurol. 2005; 252(9):1060-6. DOI: 10.1007/s00415-005-0816-x. View

14.

Maetzler W, Liepelt I, Berg D . Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol. 2009; 8(12):1158-71. DOI: 10.1016/S1474-4422(09)70291-1. View

15.

Bohnen N, Kaufer D, Ivanco L, Lopresti B, Koeppe R, Davis J . Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol. 2003; 60(12):1745-8. DOI: 10.1001/archneur.60.12.1745. View

16.

Giacobini E, Zhu X D, Williams E, Sherman K . The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology. 1996; 35(2):205-11. DOI: 10.1016/0028-3908(95)00157-3. View

17.

Whitehouse P, Price D, CLARK A, Coyle J, DeLong M . Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981; 10(2):122-6. DOI: 10.1002/ana.410100203. View

18.

Mesulam M . Alzheimer plaques and cortical cholinergic innervation. Neuroscience. 1986; 17(1):275-6. DOI: 10.1016/0306-4522(86)90242-3. View

19.

Nochi S, Asakawa N, Sato T . Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020). Biol Pharm Bull. 1995; 18(8):1145-7. DOI: 10.1248/bpb.18.1145. View

20.

. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet. 1999; 353(9169):2041-2. View